Quick Answer
Moleculin Biotech, Inc. reported Cash and Equivalents of $8.88 million for fiscal year 2025.
Moleculin Biotech, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.88M | +107.5% |
| 2024 | $4.28M | -81.8% |
| 2023 | $23.55M | -45.4% |
| 2022 | $43.15M | -39.1% |
| 2021 | $70.90M | +367.3% |
| 2020 | $15.17M | +41.3% |
| 2019 | $10.73M | +50.5% |
| 2018 | $7.13M | -7.5% |
| 2017 | $7.71M | +54.1% |
| 2016 | $5.01M | +17782.1% |
| 2015 | $28.0K | — |
| 2015 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.70M | -28.7% | -11.3% |
| June 30, 2025 | $7.56M | -30.3% | -2.1% |
| March 31, 2025 | $7.72M | -54.1% | +80.4% |
| December 31, 2024 | $4.28M | -81.8% | -54.5% |
| September 30, 2024 | $9.40M | -61.7% | -13.3% |
| June 30, 2024 | $10.85M | -66.3% | -35.5% |
| March 31, 2024 | $16.82M | -54.9% | -28.6% |
| December 31, 2023 | $23.55M | -45.4% | -4.2% |
- Moleculin Biotech, Inc. showed an increase of +107.5% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Moleculin Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: